tunity to respond to the assertion that there is little that can be done to manage risks associated with methadone prescribing in pain settings. In particular, the view that we overstate the ability to reduce risks appears overly pessimistic, may worsen methadone stigma, and is inconsistent with available data.
In order to elaborate on this point we review a study We agree with Drs. Grant and Baca that costs alone should not be driving medication considerations. Nevertheless, there appears to remain a role of methadone in the treatment of chronic pain. 4 More research and improved physician education and prescription practice guidelines may help elucidate this role.
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